NHS guidelines on prescribing cannabis-based medicines are facing a crucial test in the High Court, with campaigners arguing that existing rules bar many patients from accessing potentially life-changing treatments. Since the UK legalised medical cannabis for prescription in 2018, following high-profile cases involving children with severe epilepsy, very few NHS prescriptions have been issued – forcing most patients to pay out of pocket.
According to NHS data, only a handful of prescriptions have been written since 2018, leaving many with chronic conditions like neuropathic pain or multiple sclerosis struggling to access these treatments. The National Institute for Health and Care Excellence (NICE) guidelines, in place since 2020, set strict criteria for prescription, including demanding high-quality evidence similar to that required for traditional medicines.
Critics argue that this bar is too high, given historical research restrictions on cannabis and its complex compounds. As a result, only specific conditions – mainly severe epilepsy – are currently considered suitable for NHS prescription. The High Court challenge seeks to force a review of these guidelines and broaden the range of eligible conditions.
Proponents of the case highlight the disparity between medical cannabis's legal status and its availability on the NHS. They point to growing international evidence and patient testimonies suggesting that cannabis has therapeutic potential for various conditions, sparking calls for a more inclusive approach to prescribing.
If successful, the challenge could lead to increased demand for NHS prescriptions, requiring healthcare services to adapt their assessment and dispensing processes. The case also raises important questions about cost-effectiveness, funding models, and the broader role of cannabis-based medicines in modern healthcare.